Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dayer

Showing results (111-120 of 163) with videos related to

Pageof 17
Sort By:
Schweizerische Medizinische Wochenschrift|April 16, 1998
[Retrospective study of drug-induced agranulocytosis in hospitalized patients in Geneva and comparison with cases reported to IOCM]J C Krayenbühl, M K Oestreicher, J Sievering, et al.
Schweizerische Medizinische Wochenschrift|April 16, 1998
[Factors associated with refractory cancer pain]V Piguet, J Desmeules, A F Allaz, et al.
Schweizerische Medizinische Wochenschrift|April 16, 1998
[Genetic and environmental effects on neuromodulation and the antinociceptive effect of dextromethorphan]M K Oestreicher, J Desmeules, V Piguet, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 26, 1999
Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphanJ A Desmeules, M K Oestreicher, V Piguet, et al.
Clinical Pharmacology and Therapeutics|March 1, 1987
Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizersB Osikowska-Evers, P Dayer, U A Meyer, et al.
Clinical Pharmacology and Therapeutics|November 1, 1985
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivoU T Meier, P Dayer, P J Malè, et al.
The Journal of Biological Chemistry|September 5, 1986
Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralolJ Gut, T Catin, P Dayer, et al.
Cancer Research|February 17, 2000
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancersN Jourenkova-Mironova, K Mitrunen, C Bouchardy, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|July 30, 2013
CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian populationC Bouchardy, H Wikman, S Benhamou, et al.
Burns : Journal of the International Society for Burn Injuries|August 1, 1990
Effects of beta-blockade on energy metabolism following burnsE Breitenstein, R L Chioléro, E Jéquier, et al.
Pageof 17

Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Schweizerische Medizinische Wochenschrift|April 16, 1998
[Retrospective study of drug-induced agranulocytosis in hospitalized patients in Geneva and comparison with cases reported to IOCM]J C Krayenbühl, M K Oestreicher, J Sievering, et al.
Schweizerische Medizinische Wochenschrift|April 16, 1998
[Factors associated with refractory cancer pain]V Piguet, J Desmeules, A F Allaz, et al.
Schweizerische Medizinische Wochenschrift|April 16, 1998
[Genetic and environmental effects on neuromodulation and the antinociceptive effect of dextromethorphan]M K Oestreicher, J Desmeules, V Piguet, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 26, 1999
Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphanJ A Desmeules, M K Oestreicher, V Piguet, et al.
Clinical Pharmacology and Therapeutics|March 1, 1987
Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizersB Osikowska-Evers, P Dayer, U A Meyer, et al.
Clinical Pharmacology and Therapeutics|November 1, 1985
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivoU T Meier, P Dayer, P J Malè, et al.
The Journal of Biological Chemistry|September 5, 1986
Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralolJ Gut, T Catin, P Dayer, et al.
Cancer Research|February 17, 2000
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancersN Jourenkova-Mironova, K Mitrunen, C Bouchardy, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|July 30, 2013
CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian populationC Bouchardy, H Wikman, S Benhamou, et al.
Burns : Journal of the International Society for Burn Injuries|August 1, 1990
Effects of beta-blockade on energy metabolism following burnsE Breitenstein, R L Chioléro, E Jéquier, et al.
Pageof 17